Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746898 | 0.91 | CA9 (0.43) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL8604683 | 0.91 | PTGS2 (0.42) | CA12CA9PTGS2PTGS1 | |
| SCHEMBL7456268 | 0.86 | F10 (0.38) | CA2CA9PTGS2PTGS1 | |
| SCHEMBL7778153 | 0.82 | PTGS2 (0.49) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL6746809 | 0.80 | CA1 (0.39) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL6314705 | 0.80 | CA12 (0.39) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL6746904 | 0.77 | F10 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL6744826 | 0.76 | CA1 (0.46) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL7777723 | 0.75 | PTGS2 (0.56) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL7777697 | 0.73 | PTGS2 (0.46) | CA12CA1CA2CA9CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2002-05-16 | — | — | US | claimed |
| EP-0828718-A1 | HETEROCYCLO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038418-A1 | HETEROCYCLO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | CA12 3463/4885CA1 1781/4885CA2 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.